Skip to main content
Journal cover image

Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States.

Publication ,  Journal Article
Speicher, PJ; Gu, L; Gulack, BC; Wang, X; D'Amico, TA; Hartwig, MG; Berry, MF
Published in: Clin Lung Cancer
January 2016

BACKGROUND: This study evaluated the use of lobectomy and sublobar resection for clinical stage IA non-small-cell lung cancer (NSCLC) in the National Cancer Data Base (NCDB). METHODS: The NCDB from 2003 to 2011 was analyzed to determine factors associated with the use of a sublobar resection versus a lobectomy for the treatment of clinical stage IA NSCLC. Overall survival was assessed using the Kaplan-Meier method and Cox proportional hazard modeling. RESULTS: Among 39,403 patients included for analysis, 29,736 (75.5%) received a lobectomy and 9667 (24.5%) received a sublobar resection: 84.7% wedge resection (n = 8192) and 15.3% segmental resection (n = 1475). Lymph node evaluation was not performed in 2788 (28.8%) of sublobar resection patients, and 7298 (75.5%) of sublobar resections were for tumors ≤ 2 cm. After multivariable logistic regression, older age, higher Charlson-Deyo comorbidity scores, smaller tumor size, and treatment at lower-volume institutions were associated with sublobar resection (all P < .001). Overall, lobectomy was associated with significantly improved 5-year survival compared to sublobar resection (66.2% vs. 51.2%; P < .001, adjusted hazard ratio 0.66; P < .001). However among sublobar resection patients, nodal sampling was associated with significantly better 5-year survival (58.2% vs. 46.4%; P < .001). CONCLUSION: Despite adjustment for patient and tumor related characteristics, a sublobar resection is associated with significantly reduced long-term survival compared to a formal surgical lobectomy among patients with NSCLC, even for stage 1A tumors. For patients who cannot tolerate lobectomy and who are treated with sublobar resection, lymph node evaluation is essential to help guide further treatment.

Duke Scholars

Published In

Clin Lung Cancer

DOI

EISSN

1938-0690

Publication Date

January 2016

Volume

17

Issue

1

Start / End Page

47 / 55

Location

United States

Related Subject Headings

  • United States
  • Survival Rate
  • Retrospective Studies
  • Prognosis
  • Pneumonectomy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Lung Neoplasms
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Speicher, P. J., Gu, L., Gulack, B. C., Wang, X., D’Amico, T. A., Hartwig, M. G., & Berry, M. F. (2016). Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States. Clin Lung Cancer, 17(1), 47–55. https://doi.org/10.1016/j.cllc.2015.07.005
Speicher, Paul J., Lin Gu, Brian C. Gulack, Xiaofei Wang, Thomas A. D’Amico, Matthew G. Hartwig, and Mark F. Berry. “Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States.Clin Lung Cancer 17, no. 1 (January 2016): 47–55. https://doi.org/10.1016/j.cllc.2015.07.005.
Speicher PJ, Gu L, Gulack BC, Wang X, D’Amico TA, Hartwig MG, et al. Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2016 Jan;17(1):47–55.
Speicher, Paul J., et al. “Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States.Clin Lung Cancer, vol. 17, no. 1, Jan. 2016, pp. 47–55. Pubmed, doi:10.1016/j.cllc.2015.07.005.
Speicher PJ, Gu L, Gulack BC, Wang X, D’Amico TA, Hartwig MG, Berry MF. Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2016 Jan;17(1):47–55.
Journal cover image

Published In

Clin Lung Cancer

DOI

EISSN

1938-0690

Publication Date

January 2016

Volume

17

Issue

1

Start / End Page

47 / 55

Location

United States

Related Subject Headings

  • United States
  • Survival Rate
  • Retrospective Studies
  • Prognosis
  • Pneumonectomy
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Male
  • Lung Neoplasms
  • Humans